baber/WOPTO huggingface dataset:
Patent NZ-602398-A (NZ)
Title: A reticulate dairy based product
Inventor: CAROE CHRISTINA
IPC: A23C19/06
Filed: 2011-03-14
Abstract: Disclosed is a method for producing a reticulate dairy based product, said method comprising the steps of: (a) subjecting a dairy based product to an extrusion process to obtain multiple individual threads of the dairy based product, (b) structuring said multiple individual threads of the dairy based product to obtain a reticulate dairy based product comprising a coherent network of multiple entangled individual threads of the dairy based product, wherein the multiple individual threads of the dairy based product have a diameter below 4 mm and wherein the reticulate dairy based product has a density below 1.0 g/cm3. Also disclosed is a reticulate dairy based product comprising a coherent network of multiple entangled individual threads of a dairy based product, wherein the individual threads have a diameter below 4mm.
Patent NZ-602415-A (NZ)
Title: Chair canopy
Inventor: NIKOLIC DANIEL
IPC: A47C9/10
Filed: 2011-03-18
Abstract: Disclosed is a permanent, semi-permanent or removable chair canopy (80) which attaches to a collapsible chair frame (88). The chair canopy (80) comprises of a canopy fabric rear panel, an overhead section with a front valance and side skirts on a tubular canopy support frame (86). A bracket (84a, 84b) mounted onto the rear uprights of the collapsible chair (88) also supports the rear upright members (94a, 94b) of the canopy support frame (86). The brackets (84a, 84b) have releasable adjustment means to allow the canopy uprights (94a, 94b) to slide downward for storage and upwards when erecting the canopy (80). The fabric is supported on the rear uprights (94a, 94b) and the front extension members (98a, 98b) of the canopy support frame (86). The canopy support frame (86) collapses with collapsing of the chair frame (88) for storage, and opens out when erecting the chair for use.
Patent NZ-604790-A (NZ)
Title: Processing biomass
Inventor: MEDOFF MARSHALL
IPC: B01F27/71
Filed: 2010-05-18
Abstract: The disclosure relates to a method comprising: saccharifying a lignocellulosic material in a vessel by mixing the lignocellulosic material with a fluid medium and an enzyme, using a jet mixer, to form a mixture, wherein the jet mixer comprises a jet flow agitator that is positioned off-center relative to a vertical axis of the vessel.
Patent NZ-606091-A (NZ)
Title: Pinch valves having a multi-piece valve body to receive flexible tubing
Inventor: WENNBERG JON PETER
IPC: F16K37/00
Filed: 2011-07-01
Abstract: Pinch valves (100) having a multi -piece valve body (108) to receive flexible tubing (114) are described herein. An example pinch valve (108) includes a first body portion (118) having a first recess (144) and a second body portion (120) having a second recess (136). The first body portion (118) is movable relative to the second body (120) portion. The first recess (144) and the second recess (136) define a passageway (150) to receive a flexible tubing when the first body portion is coupled to the second body portion and the passageway is to retain the flexible tubing to prevent the flexible tubing from moving relative to the first and second body portions (118, 120) in an axial direction
Patent NZ-609052-A (NZ)
Title: Methods for treating hcv
Inventor: DUTTA SANDEEP
IPC: A61P31/14
Filed: 2012-10-19
Abstract: Provided are therapeutic regimens for the treatment of hepatitis C virus (HCV). The regimens comprise the administration of at least two direct acting antiviral agents (DAAs) and ribavirin, wherein the regimens exclude interferon and last for 6, 7, 8, 9, 10, 11 or 12 weeks. In one embodiment a regimen includes the use of ribavirin, PSI-7977 (sofosbuvir), and GS-5885 (ledipasvir).
Patent NZ-624935-A (NZ)
Title: Integrated health data capture and analysis system
Inventor: MICHELSON SETH G
IPC: G06Q50/00
Filed: 2010-10-18
Abstract: Disclosed is a system for modelling a progression of a disease within a population. The system includes at least one point-of-care (POC) device configured to receive a cartridge and an external device in data communication with the POC device. The POC device has a programmable processor and a fluid transfer device such that the POC device is at a geographical location different from the external device. Static and dynamic database components are included and have static data related to the disease and/or the population and dynamic data about the population and individual subjects respectively. A computer modelling component models the data in the static database component and the dynamic database component, thereby modelling the disease within the population. The external device provides instructions to the programmable processor to implement a change in assay protocol based on output from the computer modelling component without having to provide a new POC device to the geographical location. The instructions comprise instructions for at least a step of using the fluid transfer device of the POC device to transfer bodily fluid sample to an individual assay unit of the cartridge.
Patent NZ-625324-A (NZ)
Title: Methods of treatment using an antibody against interferon gamma
Inventor: WELCHER ANDREW A
IPC: C07K16/24
Filed: 2012-11-21
Abstract: Disclosed is the use of a monoclonal anti-human interferon gamma (anti-huIFN-γ) antibody in the manufacture of a medicament for treating a disease wherein the medicament is for use in a method comprising administering the anti-huIFN-γ at a dose of at least about 20 milligrams to not more than about 200 milligrams, wherein: - the anti-huIFN-γ antibody has a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 34 (SYWIG), a heavy chain complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 35 (IIYPGDSDTRYSPSFQG), a heavy chain complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 36 (GSYFYFDL), a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 38 (RASQSVSSSYLA), a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 41 (GASSRAT), and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 43 (QRSGGSSFT); and - the disease is selected from the group consisting of systemic lupus erythematosus (SLE), Graves’ disease, Sjogren’s syndrome, inflammatory bowel diseases including Crohn’s disease and ulcerative colitis, rheumatoid arthritis, psoriasis, multiple sclerosis, dermatomyositis, polymyositis, type I diabetes, sarcoidosis, and hemophagocytic lymphohistiocytosis.
Patent NZ-704268-A (NZ)
Title: Food and feed antioxidants and preservatives based on antioxidant enzymes extracted from animal blood
Inventor: REUKOV VLADIMIR
IPC: C11B5/00
Filed: 2013-07-16
Abstract: Disclosed is a process for extracting an antioxidant cocktail (containing a number of antioxidative molecules including but not limited to superoxide dismutase (SOD), catalase, glutathione, glutathione peroxidase) from animal sources (i.e., blood or liver) so that it can be used as a food and feed preservative in a non-purified state to prevent rancidity.
Patent NZ-709664-A (NZ)
Title: Use of fenugreek extract to enhance female libido
Inventor: BHASKARAN SUNIL
IPC: A61K36/48
Filed: 2013-12-05
Abstract: The invention is a method of enhancing female libido by administering an effective amount of a fenugreek extract, for example fenugreek seed extract, to a female in need of enhanced libido. The female can be a human female.
Patent NZ-710301-A (NZ)
Title: Humanized universal light chain mice
Inventor: STEVENS SEAN
IPC: C12N15/85
Filed: 2012-08-03
Abstract: Disclosed is a method of making a mouse comprising genetically modifying the mouse to include in its germline: (a) a humanised immunoglobulin heavy chain locus comprising at least one unrearranged human VH gene segment, at least one unrearranged human DH gene segment, and at least one unrearranged human JH gene segment operably linked to a heavy chain constant region gene; (b) a humanised immunoglobulin light chain locus comprising a single rearranged human light chain V/J sequence operably linked to a light chain constant region gene; and (c) an ectopic nucleic acid sequence encoding a mouse ADAM6 protein or ortholog or homolog or functional fragment thereof, wherein the mouse ADAM6 protein or ortholog or homolog or functional fragment thereof is expressed from the ectopic nucleic acid sequence.
Patent NZ-711772-A (NZ)
Title: Fitting for tubing containment system
Inventor: RIVEST DEAN W
IPC: F16L25/00
Filed: 2014-04-08
Abstract: A fitting for use with metal tubing is disclosed which provides an improved liquid tight seal in particular for double containment tubing systems, the fitting comprising an adaptor, the adaptor having a longitudinal passage having a longitudinal axis for fluid flow; a body for receiving the tubing, the body positioned opposite the adaptor and aligned with the longitudinal axis; a metal sealing member positioned between the adaptor and the body; a nut positioned opposite the body; a jacket lock ring positioned radially inwardly of a portion of the nut, the jacket lock ring for making a mechanical connection with an outer jacket of the tubing; and at least one fastener coupling the nut, body and adapter wherein the body includes an annular rib, the rib received in an annular pocket of the adaptor.
Patent NZ-714831-A (NZ)
Title: Diazacarbazole derivatives as tau-pet-ligands
Inventor: KOERNER MATTHIAS
IPC: C07D471/04
Filed: 2014-10-06
Abstract: The present invention relates to a compound of general formula (I) wherein R is hydrogen or tritium; F is fluoro or 18fluoro; or to a pharmaceutically acceptable acid addition salt. Compounds of formula I include 2-(6-fluoro-pyridin-3-yl)-9H-dipyrido[2,3-b;3’,4’-d]pyrrole, 3H-2-(6-fluoro-pyridin-3-yl)-9H-dipyrido[2,3-b;3’,4’-d]pyrrole and [18F]-2-(6-fluoro-pyridin-3-yl)-9H-dipyrido[2,3-b;3’,4’-d]pyrrole. The compounds may be used for binding and imaging tau aggregates and related beta-sheet aggregates including besides others beta-amyloid aggregates or alpha-synuclein aggregates.
Patent NZ-715530-A (NZ)
Title: Cxcr7 receptor modulators
Inventor: KIMMERLIN THIERRY
IPC: C07D217/04
Filed: 2014-05-28
Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R 2a, R 2b, R 3a, R 3b, R 4, L1, L2, X, Y and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.
Patent NZ-717228-A (NZ)
Title: Animal identification systems
Inventor: FRANK JOHN FINLAYSON
IPC: G06K7/10
Filed: 2014-09-08
Abstract: An animal identification system having a race including a pair of opposed walls defining a path which animals pass along and one or more readers 5 configured to read electronic animal identification devices borne by animals passing along the path through the race. The opposed walls include at least one angled wall portion that is nonparallel with the path. At least one reader 5 is mounted on the angled wall portion such that the reader is positioned at an acute angle to the path.
Patent NZ-719765-A (NZ)
Title: Spiro-oxazolones
Inventor: DOLENTE COSIMO
IPC: C07D491/12
Filed: 2014-12-16
Abstract: The present invention provides spiro-oxazolones of formula I, which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The present compounds are useful as therapeutics acting peripherally and centrally in the conditions of inappropriate secretion of vasopressin, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, aggressive behavior and phase shift sleep disorders, in particular jetlag.
Patent NZ-728721-A (NZ)
Title: Pharmaceutical nanoparticles showing improved mucosal transport
Inventor: POPOV ALEXEY
IPC: A61K47/34
Filed: 2013-05-03
Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles with one or more surface-altering agents. The particles may comprise a pharmaceutical agent selected from a corticosteroid, a receptor tyrosine kinase inhibitor, a cyclooxygenase inhibitor, an angiogenesis inhibitor, a prostaglandin analog, an NSAID, a beta blocker, or a carbonic anhydrase inhibitor, and may have a low aqueous solubility. The pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
Patent NZ-730031-A (NZ)
Title: Distance measurement device for motion picture camera focus applications
Inventor: NARANG RITESH
IPC: H04N13/00
Filed: 2015-09-23
Abstract: A system for determining a distance to a region of interest. The system may be used to adjust focus of a motion picture camera. The system may include a first camera configured to have a first field of view, and a second camera configured to have a second field of view that overlaps at least a portion of the first field of view. The system may include a processor configured to calculate a distance of the selected region of interest relative to a location by comparing a position of the selected region of interest in the first field of view with a position of the selected region of interest in the second field of view.
Patent NZ-736298-A (NZ)
Title: Control flow enhancements for lte-unlicensed
Inventor: CHEN WANSHI
IPC: H04W74/08
Filed: 2016-05-10
Abstract: Systems, methods, and apparatuses for control flow enhancement for LTE-Unlicensed (LTE-U) operation are disclosed. In one embodiment, a method includes identifying a configuration for communication using a secondary cell in a shared frequency spectrum band, wherein transmissions via the secondary cell are subject to a listen-before-talk (LBT) procedure for a shared frequency channel, identifying a transmission from the secondary cell comprising of at least one subframe, and determining a reference signal configuration for the transmission based at least in part on a cross-subframe indicator of at least one subframe. Embodiments may improve control flow in unlicensed cells by improving reference signal configuration.
Patent NZ-742168-A (NZ)
Title: Door furniture
Inventor: ROMAN CRISTINA
IPC: E05B15/00
Filed: 2018-05-02
Abstract: The invention relates to door furniture. Installing such furniture often involves assembling components on site and fixing them to a door. When doing so for many doors the task can be undesirably time consuming or otherwise inefficient. It is an object of embodiments of the invention to go at least some way towards addressing this problem. In a preferred embodiment the furniture comprises door handles 2, 3, two spindles 5 for conveying turning force from the handle, a pair of screws 20, and an escutcheon having a base 7 and a bezel 8. The spindles 5 are with the handles 2, 3 respectively. The bezel 8 can be moved with respect to the base 7 so that engagement between the bezel and heads 21 of the screws stop the bezel from coming free of the base. The furniture is formed substantially in two half-sets, each half-set being substantially pre-assembled.
Patent NZ-749991-A (NZ)
Title: Systems and methods for analyzing event data
Inventor: EVANSEN EDWARD
IPC: G06F17/18
Filed: 2011-01-05
Abstract: A computer-implemented method that predicts success of a static player formation is disclosed. The method comprises comparing the static formation to a plurality of standard formations to find a matching standard formation and determining one or more deviation types in the static formation relative to the matching standard formation. The method also includes retrieving from a database standard previous plays executed with the matching standard formation and none of the deviation types, and deviant previous plays executed with the matching standard formation and any of the deviation types, calculating a standard success percentage based on outcomes of the standard previous plays and, for each of the deviation types, a deviant success percentage based on outcomes of the deviant previous plays executed with said each of the deviation types and reporting the standard success percentage and each deviant success percentage. Methods that predict behaviour of an opposing team in a static formation and that predict the success of a dynamic-play execution are also disclosed.
Patent PT-100691-A (PT)
Inventor: CONRAD MICHAEL J
IPC: C07C69/78
Filed: 1992-07-15
Abstract: Phosphoramidites of the formula <CHEM> where R is a base-labile protecting group, R<1> and R<2> are individually alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, or aryl of 6 to 20 carbon atoms or are joined together to form with the nitrogen atom a cyclic structure of 4-7 carbon atoms and 0 to 1 annular chalcogen atoms of atomic number 8 to 16, G is a hydrocarbylene group of 1 to 20 carbon atoms and Z is a hydroxy-protected vicinal diol group bound to G by one of the vicinal diol carbon atoms or a disulfide group and bound to G by one of the sulfur atoms of the disulfide group, with the proviso that G is of at least 4 carbon atoms when Z is said disulfide group are used in conventional automated oligonucleotide synthesis to introduce a functional aldehyde or thiol group on the 5 min end of the oligonucleotide to thereby provide a reactive site on the oligonucleotide that may be used to conjugate the oligonucleotide to molecules that contain a free amino group or an electrophilic center reactive with a thiol group.
Patent PT-103057-A (PT)
Title: Panel for e.g. sliding shutter, has plate translating plane into two positions for allowing and preventing passage of light and air, respectively, where translation of plane is guided by caps and is controlled by handle
Inventor: FIGUEIREDO PEDRO MANUEL DE OLI
IPC: E06B9/02
Filed: 2003-12-31
Abstract: The panel (3) has a plate (2) provided with openings (201) and disposed in correspondence with transversal openings (101) provided in a portion of a length of profiles (1). The plate is introduced via a transversal slot (102) in the portion. The profiles are successively juxtaposed with longitudinal axes for defining a plane. The plate translates the plane into two positions for allowing and preventing passage of light and air, respectively, where the translation of the plane is guided by caps (4) and is controlled by a handle (6) that slides in another slot (103).
Patent RO-91651-A (RO)
Inventor: WEIDENBACH GUNTER
IPC: C07H3/02
Filed: 1985-02-11
Abstract: Disclosed is a process for the preparation of a solution containing glucose and fructose (isoglucose) by the conversion of a glucose-containing solution on a catalyst having glucose isomerase activity and produced on the basis of a SiO2 carrier. The productivity of the catalyst may be significantly increased by the addition of SiO2 to the glucose solution, and the catalyst according to the present invention is not damaged by temporary process shutdowns.
Patent RU-94015369-A (RU)
Inventor: GONCHAR A M
IPC: A61L12/08
Filed: 1994-04-26
Abstract: FIELD: physiological optics. SUBSTANCE: method involves using, as chemical cleaning substances, immobilized proteolytic enzymes and modified nucleases. In this case, bacterial proteases with activity 1290 to 150 proteolytic units in 1 ml, 3-6 g, and 1,4-polyalkylene oxide, 2-5 g, (water the rest) are first applied, whereupon solution of modified nucleases is used. EFFECT: enhanced efficiency of cleaning operation and antiviral protection is provided.
Patent RU-94020644-A (RU)
Inventor: TUMCHENOK V I
IPC: C02F1/00
Filed: 1994-06-02
Abstract: FIELD: joint biological and reagent iron removal from water of underground sources, preparation of water for technical usage. SUBSTANCE: proposed installation for bioreagent iron removal includes vertical shaft 1 with technological branch pipes 2, 3 and 4, perforated partitions 5 forming tiers 6 with spaces 7 of liquid at the bottom and spaces 8 of air at the top. Spaces 7 of liquid are itercommunicated by overflow pipes 9. Spaces 8 of air of tiers 6 of shaft 1 communicate with blowers 11 put on drive shaft 11. Diameter of rotors 12 of blowers 10 increases from upper space 8 of air to lower one and lower space 7 of liquid communicates with microfilter 13 and with centrifugal disintegrator 14 by sediment and through disintegrator with upper tier 6 of shaft 1 which in its turn communicates with source 15 of mineralized water and unit 16 of preparation of quick lime solution. Spaces 7 of liquid are provided in this case with unit 17 filled, for instance, with crushed quick lime, chalk, marble, etc which density is higher than that of water. EFFECT: enhanced purification efficiency, reduced cost of purification.
Patent RU-94024242-A (RU)
Inventor: SHAPOVALOV V V
IPC: B61K3/00
Filed: 1994-06-29
Abstract: FIELD: mechanical engineering. SUBSTANCE: gear pump 7 is used to deliver lubricant into working zone and return excess lubricant into lubricant container. Pump is driven from axle of wheelset of train 6. Rail lubricator housings are installed on axle 2 hinge-coupled with bearing units 5 of wheelset axles 6 of base vehicle bogie. Axes of joints coincide with axes of wheelset. EFFECT: enhanced efficiency of lubrication of rail head side surface by provision of accurate delivery of design amount of lubricant to zone of friction of rail head side surface and vehicle wheel flange; stabilization of fractional content of lubricant. 3 dwg
Patent RU-94028820-A (RU)
Inventor: PATRASENKO V S
IPC: B03C1/005
Filed: 1994-08-01
Abstract: FIELD: food processing industry, production of ecologically pure drinking water, that is good for drinking without additional household treatment (filtration, boiling) and corresponds to drinking water standards and organoleptic characteristics. SUBSTANCE: method provides production of ecologically pure magnetized water with curing and prophylaxis effect. Method provides for magnetic field action on water to produce ecologically pure magnetized water, settling and flocculation of liquid, filtration, cooling, measuring taste additions in doses (if required). Magnetic field formed at least by three separate magnetic systems located at angle of no more than 90 deg. to each other with successive alternation of polarity is generated perpendicularly to liquid stream with magnetic induction of 50 +/- 30 mT. In the case moving with speed of at least 0.9 m/min water streams is subjected to action of magnetic field. EFFECT: production of ecologically pure magnetized water with curing and prophylaxis characteristics.